This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Dilip V. Jeste, MD; Steven G. Potkin, MD; Shubha Sinha, MD; Samuel Feder, MD; Richard J. Wyatt, MD

Arch Gen Psychiatry. 1979;36(5):585-590.

Abstract
• Twenty-one hospitalized patients over 50 years of age who had tardive dyskinesia were studied for 13 months. After withdrawal of neuroleptics and antidepressants for three months, dyskinetic symptoms abated in 12 patients and persisted in nine. Discriminant function analysis showed that the persistent and reversible dyskinesia groups could be clearly separated and that the best discriminator was the number of drug-free intervals. The persistent dyskinesia group had had significantly longer neuroleptic treatment (mean, 10.8 yr) and a greater number (mean, 5.6) of drug interruptions of at least two months' duration each than did the reversible dyskinesia group. Our finding, as well as the literature reviewed, does not support the commonly held notion that frequent lengthy interruptions of long-term drug treatment reduce the incidence of persistent dyskinesia, at least in patients who are otherwise predisposed to the development of tardive dyskinesia.

Author Affiliations
From the Laboratory of Clinical Psychopharmacology, Division of Special Mental Health Research, Intramural Research Program, National Institute of Mental Health, St Elizabeth's Hospital, Washington, DC (Dr Jeste, Dr Potkin, and Dr Wyatt), and the New York Hospital and Cornell Medical Center, Westchester Division, White Plains (Dr Sinha and Dr Feder).

Footnotes
Accepted for publication Oct 25, 1978.

Reprint requests to NIMH, St Elizabeth's Hospital, WAW Bldg, Washington, DC 20032.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Maintenance Medication for Schizophrenia: Strategies for Dose Reduction
Schooler
Focus 2004;2:175-186.
ABSTRACT | FULL TEXT  

Intermittent Neuroleptic Treatment and Risk for Tardive Dyskinesia: Curacao Extrapyramidal Syndromes Study III
van Harten et al.
Am. J. Psychiatry 1998;155:565-567.
ABSTRACT | FULL TEXT  

Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert et al.
Arch Gen Psychiatry 1995;52:173-188.
ABSTRACT  

Considering Neuroleptic Maintenance and Taper on a Continuum: Need for Individual Rather Than Dogmatic Approach
Jeste et al.
Arch Gen Psychiatry 1995;52:209-212.
ABSTRACT  

Tardive Dyskinesia and Steady-State Serum Levels of Thiothixene
Yesavage et al.
Arch Gen Psychiatry 1987;44:913-915.
ABSTRACT  

Tardive Dyskinesia in Young Mentally Retarded Individuals
Gualtieri et al.
Arch Gen Psychiatry 1986;43:335-340.
ABSTRACT  

Penrsistent Tardive Dyskinesia in Bipolar Patients
Mukherjee et al.
Arch Gen Psychiatry 1986;43:342-346.
ABSTRACT  

Tardive Dyskinesia in the Aged: Duration of Treatment Relationships
Toenniessen et al.
Arch Gen Psychiatry 1985;42:278-284.
ABSTRACT  

Tardive Dyskinesia: A Discontinuation Study
Glazer et al.
Arch Gen Psychiatry 1984;41:623-627.
ABSTRACT  

Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience
Jeste and Jed Wyatt
Arch Gen Psychiatry 1982;39:803-816.
ABSTRACT  

Tardive Dyskinesia: Prevalence and Risk Factors, 1959 to 1979
Kane and Smith
Arch Gen Psychiatry 1982;39:473-481.
ABSTRACT  

Drug-Induced and Other Orofacial-Cervical Dyskinesias
JANKOVIC
ANN INTERN MED 1981;94:788-793.
ABSTRACT